HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

• ClinicalTrials.gov Identifier: NCT03940352
• Recruitment Status: Recruiting
• First Posted: May 7, 2019
• Last Update Posted: October 16, 2019
• Sponsor: Novartis Pharmaceuticals
• Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Study Description

Brief Summary:

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS.

For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8.

Two treatment arms will enroll subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and HDM201+venetoclax (treatment arm 2).

• In the treatment arm 1, subjects will receive HDM201 in combination with MBG453.
• In the treatment arm 2, subjects will receive HDM201 in combination with venetoclax. Venetoclax dose will be gradually increased (ramp-up) over a period of 4 to 5 days to achieve the daily target dose tested that will be subsequently continued.

Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with MBG453 or venetoclax in AML and high-risk MDS subjects will be determined for each treatment arm.

Condition or disease	Intervention/treatment	Phase
Acute Myeloid Leukemia (AML); High-risk Myelodysplastic Syndrome (MDS)	Drug: HDM201; Biological: MBG453; Drug: Venetoclax	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 80 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
• Actual Study Start Date: June 24, 2019
• Estimated Primary Completion Date: April 22, 2021
• Estimated Study Completion Date: April 22, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: treatment arm1: HDM201+MBG453; Phase Ib (escalation)	Drug: HDM201; Capsule; Biological: MBG453; LIVI (Liquid in vial) Concentrate for Solution for infusion
Experimental: treatment arm2: HDM201+venetoclax; Phase Ib (escalation)	Drug: HDM201; Capsule; Drug: Venetoclax; Tablet

Outcome Measures

Primary Outcome Measures :

1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety [ Time Frame: at month 24 ]
   Month 24 is assumed to be study end
2. Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety [ Time Frame: at month 24 ]
   Month 24 is assumed to be study end
3. Incidence of dose limiting toxicities (DLTs) of treatment [ Time Frame: at day 28 ]
   end of first cycle
4. Frequency of dose interuptions [ Time Frame: at month 24 ]
   Month 24 is assumed to be study end
5. Frequency of dose reductions [ Time Frame: at month 24 ]
   Month 24 is assumed to be study end
6. Dose intensities [ Time Frame: at month 24 ]
   measured in mg/ day Month 24 is assumed to be study end

Secondary Outcome Measures :

1. Overall Response Rate (ORR) [ Time Frame: at month 24 ]
   Month 24 is assumed to be study end
2. Best Overall Response (BOR) [ Time Frame: at month 24 ]
   Month 24 is assumed to be study end
3. Event Free Survival (EFS) for AML (Cheson 2003) or Progression Free Survival (PFS) for MDS (Cheson 2006) [ Time Frame: at month 24 ]
   Month 24 is assumed to be study end
4. Relapse Free Survival (RFS) for AML (Cheson 2003) or Time To Response (TTR) for MDS (Cheson 2006) [ Time Frame: at month 24 ]
   Month 24 is assumed to be study end
5. Duration Of Response (DOR) for AML (Cheson 2003) and MDS (Cheson 2006) [ Time Frame: at month 24 ]
   Month 24 is assumed to be study end
6. Presence of anti-MBG453 antibodies (treatment arm 1 HD201+MBG453) [ Time Frame: at Day 1, Day 29 and at month 24 ]
7. Concentration of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at Day 1, Day 2, Day 5, Day 6 and Day 29 ]
8. Concentration of MBG453 (treatment arm 1 HDM201+MBG453) [ Time Frame: at Day 1, Day 2, Day 8, Day 11, Day 15, Day 29 and at month 24 ]
9. Concentration of venetoclax (treatment arm 2 HDM201+venetoclax) [ Time Frame: at Day 1, Day 2, Day 3, Day 5, Day 6, Day 8, Day 9, Day 14, Day 15 and Day 29 ]
10. PK parameter (AUC) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6
11. PK parameter (Cmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6
12. PK parameter (Tmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6
13. PK parameter (AUC) of MBG453 (treatment arm 1 HDM201+MBG453) [ Time Frame: at month 6 ]
    Cycle 6
14. PK parameter (Cmax) of MBG453 (treatment arm 1 HDM201+MBG453) [ Time Frame: at month 6 ]
    Cycle 6
15. PK parameter (Tmax) of MBG453 (treatment arm 1 HDM201+MBG453) [ Time Frame: at month 6 ]
    Cycle 6
16. PK parameter (AUC) of venetoclax (treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6
17. PK parameter (Cmax) of venetoclax (treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6
18. PK parameter (Tmax) of venetoclax (treatment arm 2 HDM201+venetoclax) [ Time Frame: at month 6 ]
    Cycle 6
19. Changes from baseline in GDF-15 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) [ Time Frame: at Day 1 and Day 2 ]
20. Changes from baseline in soluble TIM-3 (Treatment arm 1 HDM201+MBG453) [ Time Frame: at month 6 ]
    Cycle 6

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Main Inclusion Criteria:

• Male or female patients ≥ 18 years of age at the date of ICF signature who present with one of the following:

  1. Relapsed/refractory AML following ≥1 prior therapies (but ≤3 prior therapies) who have relapsed or exhibited refractory disease (primary failure) and are deemed by the Investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)
  2. First line AML patient unfit for standard induction chemotherapy (includes both de novo and secondary AML), except in countries where approved therapies are available. Patients who are suitable for hematopoietic stem cell transplantation and willing to receive it are excluded.
  3. High-risk MDS patient (high and very high-risk groups according to rIPSS) who have failed hypomethylating agent therapy.
• ECOG performance status ≤ 1
• TP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and determined to contain no mutations. The TP53 status must be obtained from a bone-marrow sample, collected no longer than 3 months before signing the main ICF.
• Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutional guidelines and be willing to undergo a bone marrow aspirate and/or biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis.

Main Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

• Prior combination treatment with compounds having the same mode of action:

  • mdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in treatment arm1)
  • mdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in treatment arm2)
• History of severe hypersensitivity reactions to any ingredient of study drug(s) and other monoclonal antibodies (mAbs) and/or their excipients.
• Patients with acute promyelocytic leukemia with PML-RARA.
• Allogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD requiring systemic immunosuppressive therapy.
• GI disorders impacting absorption of oral HDM201 or venetoclax.
• Evidence of active bleeding or bleeding diathesis or major coagulopathy (including familial).
• Patients with active, known or suspected autoimmune disease (treatment arm 1 only).

Other eligibility criteria apply.

Contacts and Locations

Contacts

Contact: Novartis Pharmaceuticals; 1-888-669-6682; novartis.email@novartis.com

Contact: Novartis Pharmaceuticals; +41613241111

Locations

Australia, Victoria

Novartis Investigative Site; Recruiting

Melbourne, Victoria, Australia, 3004

Finland

Novartis Investigative Site; Recruiting

Helsinki, Finland, FIN 00290

Singapore

Novartis Investigative Site; Recruiting

Singapore, Singapore, 119228

Spain

Novartis Investigative Site; Recruiting

Madrid, Spain, 28041

Switzerland

Novartis Investigative Site; Recruiting

Basel, Switzerland, 4031

Sponsors and Collaborators

Novartis Pharmaceuticals

More Information

• Responsible Party: Novartis Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT03940352 History of Changes
• Other Study ID Numbers: CHDM201H12101C; 2018-004001-62 ( EudraCT Number )
• First Posted: May 7, 2019
• Last Update Posted: October 16, 2019
• Last Verified: October 2019

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Phase Ib; BHLRM; AML; MDS; HDM201; TP53; MBG453; TIM-3; venetoclax; Bcl-2

Additional relevant MeSH terms:

Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Myelodysplastic Syndromes; Syndrome; Disease; Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Venetoclax; Antineoplastic Agents